Welcome to our dedicated page for Scholar Rock Holding SEC filings (Ticker: SRRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scholar Rock Holding Corporation filings document the public-company record of a Nasdaq-listed biopharmaceutical issuer focused on apitegromab, spinal muscular atrophy, and myostatin biology programs. Current reports on Form 8-K cover operating and financial results, Regulation FD business updates, apitegromab regulatory disclosures, preliminary cash updates, and amendments correcting furnished earnings materials.
The company’s SEC record also includes proxy materials for director elections, auditor ratification, and advisory executive-compensation votes. Capital-structure disclosures identify SRRK common stock listed on the Nasdaq Global Select Market and include shelf registration and at-the-market offering materials for common stock sales.
Scholar Rock Holding Corporation filed a current report describing that it has resubmitted its Biologics License Application (BLA) to the FDA for apitegromab, a muscle-targeted therapy for children and adults with spinal muscular atrophy (SMA).
The company anticipates FDA acceptance of the resubmitted BLA within 30 days and a review period of up to six months, with a PDUFA action date expected in late September 2026. The resubmission also adds a second U.S. fill-finish facility alongside Catalent Indiana to support the apitegromab supply chain and planned global commercial demand. In Europe, the EMA review of the apitegromab Marketing Authorisation Application is progressing, with a decision anticipated around mid-2026.
Scholar Rock Holding Corp — an amended Schedule 13G/A shows The Vanguard Group reporting 0 shares beneficially owned of common stock following an internal realignment. The filing explains that on January 12, 2026 Vanguard disaggregated certain subsidiaries under SEC Release No. 34-39538, and the amendment is signed 03/27/2026.
Scholar Rock Holding Corporation filed an amended report to correct a scrivener’s error in its prior earnings release, updating net loss per share and weighted average shares outstanding for the quarter ended December 31, 2025.
For that quarter, the company reported a net loss of $91.0 million, or $0.76 per share, compared with a net loss of $66.5 million, or $0.61 per share, a year earlier. For full year 2025, net loss was $377.9 million, or $3.29 per share, versus $246.3 million, or $2.47 per share, in 2024. Scholar Rock highlighted progress on apitegromab for spinal muscular atrophy, noting it is ready to resubmit its BLA after FDA reinspection of Novo Nordisk’s Catalent Indiana facility, and described a new multi‑tranche financing with Blue Owl Capital, including an initial $100 million used to retire its prior Oxford Finance debt and additional tranches tied to future milestones and approvals.
Scholar Rock Holding Corporation files its annual report describing a biopharmaceutical business focused on rare neuromuscular diseases, especially spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD).
The company’s lead antibody, apitegromab, showed positive Phase 3 SAPPHIRE results in SMA, supporting improved motor function on top of existing SMN-targeted therapies. A biologics license application received FDA priority review but then a complete response letter tied to a third-party fill‑finish facility; the company plans to resubmit after cGMP issues at that facility are resolved. An EMA marketing application for apitegromab has been validated.
Scholar Rock reports a broad pipeline including subcutaneous apitegromab, SRK‑439 for neuromuscular diseases, SRK‑181 for solid tumors resistant to anti‑PD‑(L)1 therapy, and earlier programs such as SRK‑373 and SRK‑256. As of June 30, 2025, non‑affiliate common stock market value was about $2.6 billion, and as of February 26, 2026, 114,883,096 common shares were outstanding.
Scholar Rock Holding Corporation reported wider losses for the fourth quarter and full year 2025 while highlighting progress in its spinal muscular atrophy pipeline. Quarterly net loss was $90.965 million, compared with $66.454 million a year earlier, and full-year net loss was $377.939 million versus $246.294 million in 2024.
Operating expenses rose sharply, with 2025 research and development at $208.440 million and general and administrative at $176.205 million. Cash, cash equivalents and marketable securities totaled $367.563 million as of December 31, 2025, down from $437.278 million a year earlier.
The company emphasized advancing apitegromab for SMA, citing FDA engagement and readiness to resubmit its BLA after successful reinspection of Novo Nordisk’s Catalent Indiana facility. It also highlighted SRK-439, a preclinical myostatin inhibitor, and described 2026 as potentially “transformative” as it continues to invest heavily in its neuromuscular disease portfolio.
Scholar Rock Holding Corp’s chief scientific officer, Mo Qatanani, sold a total of 8,484 shares of common stock in open‑market transactions on February 23, 2026. The sales were executed under a pre‑established Rule 10b5‑1 trading plan adopted on March 31, 2025.
The transactions were split into three tranches: 7,427 shares at a weighted average price of $46.9422, 857 shares at $47.8588, and 200 shares at $48.4800, with each tranche covering multiple trades within stated price ranges. Following these sales, Qatanani’s reported holdings consist of 98,445 RSUs.
Mohammed Qatanani filed a Form 144 reporting a proposed sale of 8,484 shares of Common stock related to a Restricted Stock Award dated 02/15/2026. The filing also lists prior sales of Common stock on 12/04/2025 (136,462), 01/14/2026 (13,112), and 01/22/2026 (14,898). The broker noted is J.P. Morgan Securities LLC.
Scholar Rock Holding Corp's chief medical officer, Jing L. Marantz, reported an open-market sale of 4,157 shares of common stock on February 17, 2026 at a price of $46.5282 per share. This transaction was executed to cover tax withholding obligations arising from the vesting of restricted stock units on February 15, 2026 and was mandated under the company’s equity incentive plan rather than being a discretionary trade.
After this sale, Marantz held 126,012 shares of common stock, consisting of 29,388 shares of common stock and 96,624 restricted stock units that continue to vest annually over four years, subject to continued service with the company.
Scholar Rock Holding Corp’s general counsel, Junlin Ho, reported an open-market sale of 9,580 shares of common stock on February 17, 2026 at an average price of $46.5282 per share. According to the footnote, this sale was a mandated “sell to cover” transaction to fund tax withholding arising from the vesting of restricted stock units (RSUs) on February 15, 2026, and was not a discretionary trade.
The RSUs that vested were granted on February 13, 2023 and March 10, 2025, each representing the right to receive one share of common stock upon vesting. After this tax-related sale, Ho’s holdings consist of 131,646 shares of common stock and 109,899 RSUs, which vest annually over four years, subject to a continued service relationship with the company.
Scholar Rock Holding Corp's CHRO, Caryn Parlavecchio, reported a mandatory sale of common stock tied to tax withholding on vested RSUs. On this Form 4, she sold 9,035 shares of common stock in an open-market transaction at an average price of $46.5282 per share to cover tax obligations from restricted stock units that vested on February 15, 2026. The footnote explains this was a required "sell to cover" transaction under the company’s equity incentive plans and not a discretionary trade. After the sale, she beneficially owns 169,087 equity-linked interests, consisting of 86,859 shares of common stock and 82,228 RSUs that continue to vest annually over four years, subject to continued service.